In a pre-specified pooled analysis of VICTOR and VICTORIA, vericiguat did statistically significantly reduce the risk of the composite primary endpoint. Topline data were announced from a phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback